[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:secondary-progressive-multiple-sclerosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":38,"states":39},"Secondary progressive multiple sclerosis",4,2,[8,16,23,31],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07299019","A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis",[12],"Phase 3","RECRUITING","2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.973179Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07477639","Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.290600Z",{"nct_id":24,"title":25,"phases":26,"status":28,"updated_at":29,"content_modified":30},"NCT06961383","Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis",[27],"Phase 2","NOT_YET_RECRUITING","2026-08-26T02:15:50.539717Z","2026-05-05T02:43:29.355034Z",{"nct_id":32,"title":33,"phases":34,"status":35,"updated_at":36,"content_modified":37},"NCT06292923","A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T01:55:52.940420Z","2026-05-05T02:43:27.311283Z",[],[]]